Neil Bhowmick, PhD

home / authors / neil-bhowmick-phd

Articles

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

Bethany Smith, PhD;Sungjin Kim, MS ;Mourad Tighiouart, PhD;Edwin M. Posadas, MD;Leland Chung, PhD;Robert A. Figlin, MD;Neil Bhowmick, PhD;Jun Gong, MD
September 14th 2021

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Jun Gong, MD;Edwin M. Posadas, MD;Neil Bhowmick, PhD;Hyung L. Kim, MD;Timothy J. Daskivich, MD;Amit Gupta, MD;Howard M. Sandler, MD;Mitchell Kamrava, MD;Zachary S. Zumsteg, MD;Stephen J. Freedland, MD;Robert A. Figlin, MD
March 17th 2021

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: July 6th 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes